104 related articles for article (PubMed ID: 8556540)
41. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
42. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.
Goding S; Yang Q; Mi Z; Robbins PD; Basse PH
Cancer Gene Ther; 2007 May; 14(5):441-50. PubMed ID: 17273184
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
[TBL] [Abstract][Full Text] [Related]
44. Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness.
Govaerts AS; Guillaume T; André M; Bayat B; Feyens AM; Hawley TS; Fong AZ; Hawley RG; Symann M
Cancer Gene Ther; 1999; 6(5):447-55. PubMed ID: 10505855
[TBL] [Abstract][Full Text] [Related]
45. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
47. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
48. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
Papa MZ; Vetto JT; Ettinghausen SE; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5618-23. PubMed ID: 3489525
[TBL] [Abstract][Full Text] [Related]
49. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
[TBL] [Abstract][Full Text] [Related]
50. Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma.
Liu S; Yang H; Liang C
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):323-6. PubMed ID: 12408755
[TBL] [Abstract][Full Text] [Related]
51. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
53. Augmentation of local antitumor immunity in liver by interleukin-2 gene transfer via portal vein.
Tanji H; Yahata H; Hayamizu K; Shinozaki K; Okimoto T; Sakaguchi T; Asahara T
Cancer Gene Ther; 2002 Aug; 9(8):655-64. PubMed ID: 12136426
[TBL] [Abstract][Full Text] [Related]
54. Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects.
Jin HT; Youn JI; Choi SY; Seo SH; Park SH; Song MY; Yang SH; Sung YC
Cancer Gene Ther; 2008 Nov; 15(11):693-702. PubMed ID: 18600259
[TBL] [Abstract][Full Text] [Related]
55. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
56. Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma.
Wang Z; Qiu SJ; Ye SL; Tang ZY; Xiao X
Cancer Gene Ther; 2001 Oct; 8(10):751-8. PubMed ID: 11687898
[TBL] [Abstract][Full Text] [Related]
57. [Antitumor effect on melanoma by in vivo direct injection of packaging cells transfected recombinant IL-2 gene].
Zhu Y; Wu Y; Hui Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Apr; 19(2):154-8. PubMed ID: 10453513
[TBL] [Abstract][Full Text] [Related]
58. [The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].
Song YF; Zhao YN; Li J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):332-5, 381. PubMed ID: 8001405
[TBL] [Abstract][Full Text] [Related]
59. Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy.
Cao X; Wang J; Zhang W; Chen G; Kong X; Tani K
J Cancer Res Clin Oncol; 1995; 121(8):457-62. PubMed ID: 7642687
[TBL] [Abstract][Full Text] [Related]
60. Natural killer cells and gene therapy: potential of gene transfection for optimizing effector cell functions and for targeting gene products into tumor metastases.
Goldfarb RH; Whiteside TL; Basse PH; Lin WC; Vujanovic N; Herberman RB
Nat Immun; 1994; 13(2-3):131-40. PubMed ID: 8173234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
